OREANDA-NEWS. Lead study investigator Peter Calverley, Professor of Pulmonary and Rehabilitation Medicine, University of Liverpool, UK commented, “Exacerbations not only worsen the lung function of COPD patients and often lead to hospitalisation, they also have a significant impact on patients’ overall wellbeing. In severe cases, exacerbations even increase the risk of death. Therefore, there is an ongoing need to optimise the effect of treatment in reducing the risk of exacerbations in COPD.”

Spiriva® is the most prescribed COPD maintenance therapy worldwide.6 The leading position of Spiriva® is supported by proven clinical efficacy in reducing the risk of COPD exacerbations and improving lung function, improving quality of life in COPD patients and positive long term experience across all COPD severities.7-13 Tiotropium + olodaterol Respimat® FDC is a potential new treatment option which builds on the long term experience of Spiriva®, showing, compared to tiotropium alone, greater improvement in lung function, symptom control and health status in patients with COPD.14 It was submitted for marketing authorisation in Europe and the US in 2014.

“The value of tiotropium in reducing the risk of exacerbations is well known. Data from the TONADO® studies suggest that tiotropium + olodaterol Respimat® may reduce the risk of exacerbations even further than tiotropium alone. We look forward to further evaluating the effect of this potential new treatment on exacerbations in a dedicated exacerbation study.” Professor Peter Calverley added.

DYNAGITO® is part of the extensive TOviTO® clinical trial programme for tiotropium + olodaterol Respimat® FDC. TOviTO®, which also encompasses the already reported TONADO®,14 VIVACITO®,15 and TORRACTO®16 studies, includes 12 clinical trials in total. Once DYNAGITO® is completed, TOviTO® will involve over 15,000 patients in more than 50 countries.